Business in Brief
What’s new in business – SARS-CoV-2 and beyond
Olivia Gaskill | | Quick Read
Proof-of-concept tests for rapidly detecting SARS-CoV-2 and influenza have been developed by AnteoTech (1). The highly sensitive tests, which should be available within six to nine months, could reduce the spread of COVID-19 by identifying individuals with low viral load.
The Native Antigen Company has announced a custom contract service to provide scientists with rapid access to antigen panels for existing influenza strains. Commercial Director Andy Lane says this is “vital to help distinguish infection from that of other respiratory diseases and to enable accurate diagnosis and treatment (2).”
Read the full article now
Log in or register to read this article in full and gain access to The Pathologist’s entire content archive. It’s FREE!
Or register now - it’s free!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Pathologist magazine